<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:5910028;
mso-list-template-ids:-1793184704;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:89199961;
mso-list-template-ids:1078349680;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:1018190966;
mso-list-template-ids:-1422853410;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:2016346149;
mso-list-template-ids:-2141009854;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://professional.diabetes.org/sites/professional.diabetes.org/files/media/ada-2022_nutritionlifestyle_rfa_final_1.pdf">American Diabetes Association: Leveraging Nutrition
and Lifestyle for Diabetes Prevention Across the Life Span</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The American Diabetes Foundation is soliciting research to improve the adoption of lifestyle modifications at the individual and community level with interventions tailored to different
racial and socioeconomic groups across the life span. Applicants should indicate how the proposed research will have a significant impact (“move the needle”) on outcomes in those individuals at risk of, or living with, diabetes. This RFA prioritizes nutritional
and/or physical activity interventions that more effectively incorporate cultural or personal preferences, psychological supports, comorbid conditions, socioeconomic status, food insecurity, and other factors that may impact consistency with an eating and/or
exercise plan and its effectiveness; approaches that better tailor medical nutrition therapy and diabetes self-management education and support to different racial and socioeconomic groups in sustainable real-world settings; behavioral interventions that help
encourage and sustain health diet and increased physical activity; comparison and/or utilization of different delivery methods aided by wearable technology (e.g. accelerometers, continuous glucose monitors, etc.); and cost-effectiveness studies in support
of third-party coverage and policy change.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of Intent due November 22, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: November 8 (due to Veterans Day holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.rivkin.org/research/apply/" target="_blank">Marsha Rivkin Center for Ovarian Cancer: Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.rivkin.org/research/grants/pilot-study-awards/" target="_blank">Pilot Study Program</a><br>
Two-year awards of total $75,000. Pilot Study Program awards will support investigator-initiated projects in all areas of ovarian cancer research. In addition, projects designed to analyze data from already funded clinical trials will be considered. Funds are
for direct costs only.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: November 15 (due to Thanksgiving holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.rivkin.org/research/grants/scientific-scholar-awards/" target="_blank">Scientific Scholar Award</a><br>
Two-year grants at $120,000 each, Scientific Scholar Awards are intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research. Funds are for direct costs only.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: November 15 (due to Thanksgiving holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.mcknight.org/programs/the-mcknight-endowment-fund-for-neuroscience/technology-awards/" target="_blank">McKnight Foundation: Technological Innovations in Neuroscience
Awards</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The program seeks to advance and enlarge the range of technologies available to the neurosciences. It does not support research based primarily on existing techniques. The Endowment Fund
is especially interested in how technology may be used or adapted to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism. Technology may take any form, from biochemical tools to instruments to software
and mathematical approaches. A goal of the Technological Innovations awards is to foster collaboration between the neurosciences and other disciplines; therefore, collaborative and cross-disciplinary applications are explicitly invited. Up to $100,000 per
year for two years. Funds may be used toward a variety of research activities but not the recipient’s salary.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of Intent due December 6, 20121.
<span style="color:red">Med-RA deadline to receive draft documents: November 18 (due to Thanksgiving holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://chanzuckerberg.com/rfa/single-cell-data-insights/">Chan Zuckerberg Initiative: Data Insights from Existing Single-Cell Datasets</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Chan Zuckerberg Initiative (CZI) seeks applications for projects that aim to use and gain insights into health and disease from existing single-cell datasets to help accelerate progress
toward challenges associated with the compilation and exploration of large atlas-scale data. Given the growth of single-cell biology and the rapid increase in available data, CZI is looking to support projects that will advance the fields of single-cell biology
and data science. Grantees will be expected to interact with a network among participating groups that builds community and accelerates progress. Applications are encouraged from computational experts outside the field of single-cell biology but with expertise
relevant to overcoming current bottlenecks. Projects may include dedicated efforts to refine existing computational tools, benchmark classes of tools, improve standards, integrate available data that enables greater biological insight, develop new features
that support interoperability of data or tools, and other major challenges brought forward.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">18-month projects; focused projects: $200,000; expanded projects: $400,000.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 14, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: December 1.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-22-001.html">NIH Health Care Systems Research Collaboratory – Pragmatic and Implementation Trials of Embedded Interventions
(UG3 / UH3, Clinical Trials Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages UG3 / UH3 phased cooperative research applications to conduct efficient, large-scale pragmatic or implementation trials to improve
health and care delivery, with a particular focus on health care systems (HCS) with less historical involvement in research studies focused on improving health outcomes for US patient populations. Awards made under this FOA will initially support a one-year
milestone-driven planning phase (UG3), with possible transition to a trial conduct phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase.
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The overall goal of this initiative is to support the “real world” assessment of health care strategies and clinical practices and procedures in HCS that lead to improved care for populations
in a variety of healthcare contexts, with a strong focus on populations with health disparities. Results from the pragmatic studies supported by this FOA should inform policy makers, payers, doctors and patients across diverse patient care settings. This FOA
requires that the intervention under study be embedded into health care delivery system, “real world” settings. Studies can propose to integrate multimodal or multiple interventions that have demonstrated efficacy into HCS; or implement HCS changes to improve
adherence to evidence-based guidelines. Trials should be conducted across three or more health care systems (HCS) that provide care to patient populations and will become part of and work with the NIH HCS Research Collaboratory.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 15, 2021 and June 2, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for December 2021 due date: December 2.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Expanding Differentiated Care Approaches for Adolescents Living with HIV (R34 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-106.html">R34</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement invites applications for Planning Grants (R34) that will develop and pilot test differentiated models of care for adolescents and young adults (referred
to in this FOA as youth) who are living with HIV around the world. Differentiated care models can be designed to maintain or improve health outcomes along the HIV care continuum for youth who are living with HIV.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-105.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement invites applications for Research Project Grants (R01) that will evaluate differentiated models of care for adolescents and young adults (referred
to in this FOA as youth) who are living with HIV around the world. Differentiated care models can be designed to maintain or improve health outcomes along the HIV care continuum for youth living with HIV.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 6, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: December 13 (due to Winter break).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-049.html" target="_blank">Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not
Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation
due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies”, or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated
with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for “liquid biopsies”, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and
saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the
understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based
standardization of biopsy handling practices.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 11, 2022; June 7, 2022; September 13, 2022; January 11, 2023; June 7, 2023; September 13, 2023; January 11, 2024; June 7, 2024; and September 13, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for January 2022 due date: December 13 (due to Winter break).</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-004.html">Cellular Senescence Network: Technology Development and Application in Human Systems (UG3/UH3 Clinical Trial
Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to solicit novel analytics and technologies to identify senescent cells in human tissues This FOA supports the accelerated
proof-of-principle demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to multiple human The purpose of this FOA is to solicit applications for the development of novel, untested analytics and
technologies to identify and map senescent cells in human tissues at high resolution. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to
multiple human tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in mammalian tissues. The subsequent UH3 phase is to support
initial validation in human tissues, optimization and scale-up, and generation of production level data. Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable
milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 18, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: January 4 (due to MLK holiday).</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-005.html">Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial
Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this FOA is to solicit novel analytics and technologies to identify and map senescent cells in murine tissues at high resolution. This FOA supports the accelerated proof-of-principle
demonstration of promising tools, techniques and methods that can be integrated, scaled, and applied to multiple murine tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in
the identification and mapping of senescent cells in murine tissues. The subsequent UH3 phase is to support initial validation in multiple murine and/or human tissues, optimization and scale-up, generation of production level data and the application of the
technology to describe cellular senescence in a mouse life course situation (for example development or lifespan).
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 19, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: January 5 (due to MLK holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=334400">Maternal and Child Health Secondary Data Analysis Research (MCH SDAR)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of the Maternal and Child Health Secondary Data Analysis Research (MCH SDAR) Program is to support applied MCH research that utilizes the secondary analysis of existing national
data sets and/or administrative records to improve the health and well-being of MCH populations. The MCH SDAR program provides the opportunity for researchers across the nation to build the MCH evidence base by using existing data sets, such as national data
sets and/or administrative records, to identify emerging issues, study new research questions, test hypotheses, and determine pathways for intervention. Existing and emerging public health challenges affecting MCH populations including children with special
health care needs require timely, evidence-based responses from MCH programs, policy, and practice. Without sufficient evidence or data, it is challenging to develop interventions addressing both existing and emerging MCH issues. This program will allow us
to achieve timely, evidence-based responses to these challenges. HRSA will fund approximately six 1-year projects at $100,000 per project.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due January 26, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: January 12 (due to MLK holiday).</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.nsf.gov/pubs/2022/nsf22510/nsf22510.htm">NSF Ideas Lab: Dark Dimensions of the RNA Regulome</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This solicitation invites participation in an Ideas Lab whose focus will be the exploration of novel approaches to elucidate the evolutionary and functional significance of RNA transcripts
that do not encode proteins as well as the technological innovations that may arise from the ability to harness the power of non-coding RNA to solve pressing societal problems. Ideas Labs are intensive, facilitated workshops to find innovative solutions to
grand challenge problems. The overarching aim of this Ideas Lab is to bring together a diverse set of researchers from multiple disciplines spanning biology, chemistry, physics, mathematics, computer and information sciences, and engineering, to stimulate
generation and execution of innovative research that advances our understanding of the origin, diversity, and functions of non-coding RNAs. Outcomes from this Ideas lab should lead to new theories and models for understanding non-coding RNAs, new approaches
to manipulate and control non-coding RNA activity, and biotechnological innovations based on the expected research results that spur the bioeconomy and enhance our ability to predict and mitigate the effects of changing environments on organisms and ecosystems.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Preliminary proposal due January 31, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: January 18.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-075.html">Identification and Characterization of Persistence Mechanisms of Select Protozoan Pathogens (R01 Clinical Trial
Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to expand our understanding of protozoan parasite persistence mechanisms and provide research tools and strategies to enable identification
and credentialing of novel treatments for persistent protozoan pathogens.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: January 26.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">New York Stem Cell Foundation: Stem Cell and Neuroscience Investigator Awards</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://nyscf.org/programs/extramural-grants/applicants/stem-cell-investigator-awards/" target="_blank">Robertson Stem Cell Investigator Awards</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">NYSCF is soliciting applications from early career investigators for awards to be used for exploring the basic biology and translational potential of stem cells. The aim of this initiative
is to support highly innovative, emerging scientists whose pioneering approaches have the potential to transform the field of stem cell research, and advance understanding and use of stem cells in the development of treatments for human disease. This career
development award provides up to $1.5 million in flexible funding over 5 years. No institutional overhead is provided.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">To be eligible, candidates must:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Have completed one or more of the following degrees: MD, PhD, DPhil<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Be within 6 years of starting a faculty (professorship) or comparable position on June 1, 2022 (Note: an additional year of eligibility was added as a
result of the COVID-19 crisis)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Independently supervise a research team as head of group/laboratory<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Have a publication record containing articles that are innovative and high impact<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 16, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: February 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://nyscf.org/programs/extramural-grants/applicants/neuroscience-investigator-awards/" target="_blank">Robertson Neuroscience Investigator Awards</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">NYSCF is soliciting applications from early career investigators for awards in neuroscience. The goal of this initiative is to foster innovative, emerging scientists whose pioneering approaches
have the potential to transform the field of neuroscience. <b>For the 2022 application cycle, applicants are invited to apply from all fields in neuroscience. NYSCF especially encourages applications from neuroscientists whose research areas may be under-supported
by traditional funding mechanisms and/or underrepresented in the field as a whole. Applicants need not be working in areas related to stem cells or related areas</b>. This career development award provides up to $1.5 million in flexible funding over 5 years.
No institutional overhead is provided.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">To be eligible, candidates must:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Have completed one or more of the following degrees: MD, PhD, DPhil<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Be within 6 years of starting a faculty (professorship) or comparable position on June 1, 2022 (Note: an additional year of eligibility was added as a
result of the COVID-19 crisis)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Independently supervise a research team as head of group/laboratory<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Have a publication record containing articles that are innovative and high impact<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 16, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: February 3.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-070.html">Advancing Group A Streptococcus Vaccine Discovery (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement is to support discovery and design of novel Group A Streptococcus (GAS) vaccine candidates and their advancement into preclinical evaluation
for broad protection against GAS infections.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 18, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: February 7.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-001.html">Understanding the Role of Bilingualism in Cognitive Reserve/Resilience in Aging and AD/ADRD (R01 Clinical Trial
Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this Funding Opportunity Announcement (FOA) is to support research studying the role of bilingualism as it relates to cognitive reserve/resilience in healthy aging and in Alzheimer’s
disease (AD) and Alzheimer’s disease-related dementias (ADRD). This FOA aims to address the need for more prospective, hypothesis-driven research to build a theoretical framework and to clearly identify the extent to which acquiring a second language impacts
human brain function. Multimodal and multidisciplinary studies are highly encouraged to improve our understanding of the complex interactions between neural, environmental, and sociocultural factors and the role of bilingualism in healthy aging and in AD/ADRD.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 3, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: February 14.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-002.html">Cell-Specific Impact of Liquid-Liquid Phase Separation in Aging and AD/ADRD (R21 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this Funding Opportunity Announcement is to support research to identify cell-specific mechanisms in biomolecular condensate (BMC) formation and function, providing novel information
for the role BMCs play in diverse cell types in the context of aging and neurobiology of Alzheimer’s disease (AD) or AD-related dementias (ADRD). This research should enhance our understanding of the cell-specific mechanistic role of BMCs in aging and AD/ADRD
and serve as the foundation for more comprehensive etiological studies that might lead to the development of future BMC-based therapies for age-related neurodegenerative diseases.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 3, 3022.
<span style="color:red">Med-RA deadline to receive draft documents: February 14.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-005.html">Promoting Reproductive Health for Adolescents and Adults with Disabilities (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement invites grant applications that address gaps in our understanding of best practices for promoting reproductive health across the transition from adolescence
to adulthood for persons with disabilities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 20, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: March 8.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b>CoM’s
unofficial funding opportunities blog</b></a><b>.</b><o:p></o:p></span></p>
</div>
</body>
</html>